NCT00734292 - Single-dose Crossover Study to Evaluate the Early Bronchodilating Effect of FlutiForm HFA pMDI in Adult Subjects With Mild to Moderate Asthma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

September 30, 2008

Primary Completion Date

September 30, 2008

Study Completion Date

October 31, 2008

Conditions

Mild to Moderate Asthma

Interventions

DRUG

fluticasone propionate, formoterol fumarate

"● Period 1 Treatment Regimen A: FlutiForm 250/10 ug~FlutiForm HFA pMDI (250/10 ug); (two actuations of FlutiForm HFA pMDI 125/5 ug/actuation)~● Period 2 Treatment Regimen B: FlutiForm 100/10 ug~FlutiForm HFA pMDI (100/10 ug); (two actuations of FlutiForm HFA pMDI 50/5 ug/actuation)~● Period 3 Treatment Regimen C: placebo~SKP placebo; (two actuations)"

OTHER

fluticasone propionate, formoterol fumarate

"● Period 1 Treatment Regimen B: FlutiForm 100/10 ug~FlutiForm HFA pMDI (100/10 ug); (two actuations of FlutiForm HFA pMDI 50/5 ug/actuation)~● Period 2 Treatment Regimen C: placebo~SKP placebo; (two actuations)~● Period 3 Treatment Regimen A: FlutiForm 250/10 ug~FlutiForm HFA pMDI (250/10 ug); (two actuations of FlutiForm HFA pMDI 125/5 ug/actuation)"

OTHER

fluticasone propionate, formoterol fumarate

"● Period 1 Treatment Regimen C: placebo~SKP placebo; (two actuations)~● Period 2 Treatment Regimen A: FlutiForm 250/10 ug~FlutiForm HFA pMDI (250/10 ug); (two actuations of FlutiForm HFA pMDI 125/5 ug/actuation)~● Period 3 Treatment Regimen B: FlutiForm 100/10 ug~FlutiForm HFA pMDI (100/10 ug); (two actuations of FlutiForm HFA pMDI 50/5 ug/actuation)"

Trial Locations (8)

23229

Investigational Site, Richmond

33594

Investigational Site, Valrico

53227

Investigational Site, West Allis

80230

Investigational Site, Denver

92691

Investigational Site, Mission Viejo

92801

Investigational Site, Anaheim

97213

Investigational Site, Portland

97504

Investigational Site, Medford